Trials / Completed
CompletedNCT00162318
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cetuximab + Gefitinib | IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression. |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2006-04-01
- Completion
- 2006-04-01
- First posted
- 2005-09-13
- Last updated
- 2015-10-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00162318. Inclusion in this directory is not an endorsement.